Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 3Lymphoma, Non-Hodgkin 3Recurrence 2Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Neoplasm Metastasis 1Lymphatic Diseases 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 108Rituximab 62Etoposide 56Methotrexate 52Cytarabine 52Peripheral Blood Stem Cell Transplantation 47Vincristine 45Filgrastim 43fludarabine phosphate 41Radiotherapy 37Mycophenolic Acid 35Doxorubicin 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Antilymphocyte Serum 27Dexamethasone 26Cyclosporine 26Melphalan 24merphos 20blinatumomab 20Leucovorin 20Granulocyte Colony-Stimulating Factor 16Carmustine 15fludarabine 14Ifosfamide 14Calcium Dobesilate 14CT-P10 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × sepantronium × Clear all
NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Cothera Bioscience, Inc

Phase 2 Active not recruiting
14 enrolled
Lymphoid

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡